Rasputin_Vol
"Slava Ukraina"
- Joined
- Aug 14, 2007
- Messages
- 72,056
- Likes
- 39,845
Yeah... they don't want to make money. That is the angle I figured you would use. It couldn't possibly be that they already have an alternative coming down the pike that will be far more expensive than Ivermectin, which is a couple of dollars.Ya. They don’t want to make money.
Their study is peer reviewed.
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic | Nasdaq
Merck MRK announced that it has signed a procurement agreement with the United States government for its COVID-19 therapeutic candidate, molnupiravir (MK-4482). Per the agreement, the government will purchase 1.7 million courses of the candidate for approximately $1.2 billion, if the drug is granted Emergency Use Authorization or approval from the FDA.
Merck is developing molnupiravir in partnership with Ridgeback Biotherapeutics in a phase III study for the treatment of non-hospitalized patients with confirmed COVID-19. Merck is currently developing molnupiravir as an oral treatment for outpatients with COVID-19 in a phase III study — MOVe-OUT.